Compare Figs Inc (FIGS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs TransMedics Group Inc — how do they compare? Figs Inc trades at $15.6 (market cap $2.49B), while TransMedics Group Inc trades at $77.85 (market cap $2.74B). The key difference: Figs Inc and TransMedics Group Inc are close in size by market cap, and Figs Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and TransMedics Group Inc for 24 Days on average.
| FIGS | TMDX | |
|---|---|---|
Market Cap | $2.49B | $2.74B |
Volume | 5,964,311 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $150.42 |
52-Week Low | $6.90 | $61.99 |
Typical Hold Time | 33 Days | 24 Days |
Enterprise Value | $2.25B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $15.78, up 12.23% over the past day, reflecting strong momentum. The technical outlook is bullish, supported by moving averages, while recent earnings beats and raised 2026 guidance highlight fundamental strength. Revenue growth accelerated to 28.8% in Q2 2026, with international sales surging 67%, and the company maintains a high gross margin of 68.91%.
The investment outlook is positive, with a consensus price target of $18.00 implying 14% upside. However, risks include a rich valuation (P/E of 45.39) and execution challenges in sustaining growth. Analyst sentiment is predominantly bullish, with 60% recommending buy, but investors should monitor margin pressures and competitive dynamics.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
